Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle… Read More
Editor’s note: William Canestaro is managing director at Seattle venture capital firm WRF Capital and leads the biotechnology investment team. Seagen’s sale to Pfizer would have seemed unthinkable a few… Read More
Pfizer’s plan to acquire Seagen for $43 billion has cleared the necessary regulatory hurdles, the pharma titan announced Tuesday. The deal will close on Thursday. Seagen is the largest biotech… Read More
Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors. Siegall… Read More
Seagen fielded multiple offers before agreeing to a whopping $43 billion acquisition by pharma giant Pfizer. The Seattle-area company revealed negotiation details with several companies in a recent SEC filing… Read More
Clay Siegall is proud of his legacy as co-founder and longtime CEO of Seagen, the largest biotech company in the Seattle area. “I built a great company,” Siegall said in… Read More
Seagen founder Clay Siegall is jumping back into the biotech world as CEO and president of Morphimmune. Founded in 2020, the Purdue University spinout will relocate its headquarters to the… Read More
Seattle-area biotech experts are eying the past warily in the wake of this week’s news that Pfizer plans to acquire Bothell, Wash.-based Seagen for a whopping $43 billion. Most previous… Read More
Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed. Whether that happens to Seagen is a big question that will impact the Seattle-area biotech community.… Read More
Pfizer is buying Seattle-area biotech giant Seagen in a massive $43 billion deal announced Monday. The deal is the largest biopharma transaction in three years, and comes after reports emerged… Read More
Biopharma giant Pfizer is eyeing an acquisition of Seagen, the biggest biotech company in the Seattle area, according to a report in the Wall Street Journal Monday. Talks between the companies are… Read More
A biotech startup spun out of the University of Washington and led by veterans of Seattle-area biotech giant Seagen has raised $4.4 million, part of an ongoing seed round. The… Read More
Clay Siegall, the former CEO and chairman of Seattle-area biotech giant Seagen, will not face charges stemming from an arrest at his home in April. The Seattle Times first reported… Read More
Sujal Patel has been here before. He weathered the 2009 recession as CEO of Isilon Systems, coming out the other end to sell his company the next year for $2.25… Read More
— Seattle biotech giant Seagen has appointed a new CEO, David Epstein, a former executive at Novartis. Epstein also joined the company’s board of directors. Epstein take the helm of… Read More
Seagen has inked a deal to develop, manufacture and commercialize an experimental immuno-oncology agent from Lava Therapeutics, a biotech company based in Utrecht, Netherlands. Seagen will pay Lava $50 million… Read More
Seagen reported second quarter revenue of $498 million, up 28%, beating analyst expectations. The company also recently reported “positive” early data from a trial testing its drug Padcev in combination… Read More
A new Wall Street Journal report revealed that Merck is in “advanced talks” to acquire Seattle-area biotech giant Seagen in a deal that could be worth $40 billion or more.… Read More
Biopharma giant Merck is considering an acquisition of Seagen, the Seattle area’s biggest biotech company, according to a report in the Wall Street Journal Friday. The Journal reported that “talks… Read More
Here’s a rundown of life sciences and health news across the Pacific Northwest this week. Talus Bioscience raised $9.75 million. The drug discovery company is led by its scientist founders,… Read More
It was a week of accolades, partnerships and new programs in the Pacific Northwest life sciences scene. University of Washington geneticist Evan Eichler landed on Time magazine’s list of “100… Read More
Here’s a rundown of the top life sciences and health news across the Pacific Northwest this week. Seagen CEO resigns after domestic violence arrest: Clay Siegall resigned as CEO and… Read More
Clay Siegall has resigned as CEO and chairman of Seagen in the midst of domestic violence allegations, more than 24 years after the biotech veteran helped start the publicly traded… Read More
Seagen is expanding its manufacturing capacity in the Seattle area. The fast-growing global biotech company will build a 270,000 square-foot facility to make antibody-based drugs north of its U.S. headquarters… Read More
This week we highlighted the finalists for Health Innovation of the Year at the GeekWire Awards. The finalists showcase the strength of science and innovation in the Pacific Northwest. That… Read More
ProfoundBio, based in Woodinville, Wash., and Suzhou, China, has raised $55 million in a Series A funding round to advance its programs developing new anti-cancer agents. The company is led… Read More